Research library

Key finding

A 2025 systematic review included 35 preclinical studies and one small clinical report. Animal models described improved structural, functional, and biomechanical outcomes across muscle, tendon, ligament, and bone injuries.

Key finding

Axonal and neuronal necrosis, demyelination, and cyst formation were counteracted.

Key finding

This review found consistently favourable healing signals across rodent tendon, ligament, and skeletal-muscle injury models, including functional and structural recovery measures.

Key finding

BPC157 displays protective activity in various organs and tissues.

Key finding

In a retrospective telephone follow-up, 14 of 16 contacted patients reported knee-pain relief after intra-articular BPC-157 alone or combined with TB4.

Key finding

In rat hind-limb ischaemia and endothelial-cell models, BPC-157 increased vessel formation and blood-flow recovery while activating VEGFR2-Akt-eNOS signalling.

Key finding

Topical BPC-157 accelerated closure of alkali-burn wounds in rats and was associated with stronger granulation, re-epithelialisation, collagen deposition, endothelial-cell migration, and angiogenic signalling.

Key finding

BPC 157 is a fundamental treatment that quickly restores blood supply to the ischemically injured area and rapidly activates collaterals.

Key finding

BPC 157, a pentadecapeptide derived from human gastric juice, has been demonstrated to promote the healing of different tissues, including skin, muscle, bone, ligament and tendon in many animal studies.

Key finding

We improved medial collateral ligament (MCL) healing throughout 90 days after surgical transection.

Key finding

Pentadecapeptide BPC 157, composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice.

Key finding

Angiogenesis is a natural and complex process controlled by angiogenic and angiostatic molecules, with a central role in healing process.

Key finding

Sulphasalazine (50 mg/kg) and 6-alpha-methylprednisolone (1 mg/kg) were given once daily intraperitoneally.

Key finding

Stable gastric pentadecapeptide BPC 157 (BPC 157, as an antiulcer agent in clinical trials for inflammatory bowel disease; PLD-116, PL 14736, Pliva, no toxicity reported) alone (without carrier) ameliorates healing of tendon and bone, respectively, as well as other tissues.

Key finding

We report complete transection of major muscle and the systemic peptide treatment that induces healing of quadriceps muscle promptly and then maintains the healing with functional restoration.

Key finding

In studies intended to improve healing of transected Achilles tendon, effective was a stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W.

Key finding

Gastrectomy often results in increased likelihood of osteoporosis, metabolic aberration, and risk of fracture, and there is a need for a gastric peptide with osteogenic activity.

Key finding

Recent Advances: BPC 157 has practical applicability (given alone, with the same dose range, and same equipotent routes of application, regardless the injury tested).

Key finding

We reviewed again the significance of the stable gastric pentadecapeptide BPC 157 as a likely mediator of Robert's stomach cytoprotection/adaptive cytoprotection and organoprotection and as novel mediator of Selye's stress coping response to reestablish homeostasis.

Key finding

The study reports that studies also report reduced inflammatory cytokine activity, improved microvascular integrity, and beneficial effects on pain modulation through peripheral and dopaminergic mechanisms.